Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Add as a preferred source on Google
UTRECHT, The Netherlands, Aug. 09, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017 at 9:45 a.m. ET.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ lead bispecific antibody candidate, MCLA-128, is expected to begin a Phase 2 combination trial in the second half of 2017 in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus’ second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145 designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation.
Contacts: Media: Eliza Schleifstein +1 973 361 1546 [email protected] Investors: Kimberly Minarovich +1 646 368 8014 [email protected]
